BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210924T094500
DTEND;TZID=America/New_York:20210924T160000
DTSTAMP:20210812T195235Z
CREATED:20210812T195020Z
LAST-MODIFIED:20210812T195235Z
UID:49495-1632476700-1632499200@globalbiodefense.com
SUMMARY:Review of Third-Party Research Risk: Is There a Role for IRBs?
DESCRIPTION:“Review of Third-Party Research Risk: Is There a Role for IRBs?\,” an HHS Office for Human Research Protections (OHRP) Exploratory workshop\, will be livecast on 24 September 2021. \nThe research community has generally focused on the protection of human research subjects as defined by the\nCommon Rule. However\, sometimes the conduct of research can have an impact on people who are third parties\nand who do not meet the definition of human subjects. This meeting will explore who some of the impacted parties are and what types of risks they might face in various types of research. It will further explore the idea of expanding regulatory protections to cover third parties in some circumstances. Panelists will discuss whether and what support for this idea already exists in the field of research ethics and whether institutional review boards (IRBs) have a role to play in oversight of such protections should they be warranted. \nHighlighted sessions include: \n\nPanelists will consider whether researchers and the research community have a responsibility to protect third parties and if so\, in what capacity.\nResearch Studies That Do Not Directly Involve Human Subjects\nThird-Party Risk in Clinical Research Trials\nEnsuring Privacy\, Building Trust: Collecting\, Processing\, and Sharing Third-Party Information in Social\nand Behavioral Health Research\nEthical Considerations for Third-Party Risk in Research\nLimiting Non-Consenting Third Parties to Reasonable Research Risks\nPublic Risk Perception and the Creation of Clear Communications\nReviewing Third-Party Risks: A Proposed Framework for IRBs (and Researchers)\nAre IRBs the Right Oversight Bodies for Protecting Third Parties?\n\nVideos of each session will be available on the HHS OHRP website after the event. All Exploratory Workshop sessions meet the Certified IRB Professional (CIP) recertification guidelines exit disclaimer icon and are eligible for a maximum of 5 hours of credits.
URL:https://globalbiodefense.com/event/review-of-third-party-research-risk-is-there-a-role-for-irbs/
CATEGORIES:Conference,Continuing Education
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/08/ohrp-review-third-party-research-risk-role-irb-clinical-trial-bioethics.jpg
LOCATION:https://videocast.nih.gov/watch=41987
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210924T110000
DTEND;TZID=America/New_York:20210924T180000
DTSTAMP:20210923T225050Z
CREATED:20210901T222906Z
LAST-MODIFIED:20210923T225050Z
UID:49743-1632481200-1632506400@globalbiodefense.com
SUMMARY:Developing a Long-Term Strategy for Low-Dose Radiation Research in the U.S.
DESCRIPTION:Join the Committee on Developing a Long-Term Strategy for Low-Dose Radiation Research in the United States at its third public meeting on Friday\, September 24. The Committee will hear from federal agencies\, research institutes\, and international organizations on coordination of low-dose radiation research. \nHighlighted topics include: \n\nCoordination of Low-Dose Radiation Research with the National Cancer Institute (NCI)\nQ+A with the Committee and Staff\nCoordination of Low-Dose Radiation Research with the Nuclear Energy Agency-Organisation for Economic Cooperation and Development (NEA-OECD)\nCoordination of Low-Dose Radiation Research with the National Institute of Allergy and Infectious Diseases (NIAID)\n\nBACKGROUND \nThe National Academies of Sciences\, Engineering\, and Medicine will perform a study and provide a report with findings and recommendations on the current status and development of a long-term strategy for low-dose radiation research in the United States. Specifically\, the objectives of the study will be to: \n1. Define the health and safety issues that need to be guided by an improved understanding of low dose and low dose rate radiation health effects. \n2. Identify current scientific challenges for understanding low dose and low dose rate radiation health effects. \n3. Assess the status of current low dose radiation research in the United States and internationally. \n4. Recommend a long-term strategic and prioritized research agenda to address scientific research goals for overcoming the identified scientific challenges in coordination with other research efforts and support education and outreach activities to disseminate information and promote public understanding of low-dose radiation. \n5. Define the essential components of the research program that would address this research agenda within the universities and National Laboratories. \n6. Address coordination between federal agencies (including the National Institutes of Health\, the National Science Foundation\, National Aeronautics and Space Administration\, and different DOE offices) and with international efforts to achieve objectives. \n7. Identify and\, to the extent possible\, quantify\, potential monetary and health-related impacts to Federal agencies\, the general public\, industry\, research communities\, and other users of information produced by such research program. \nThe National Academies will prepare a report with findings and recommendations that addresses the objectives above. \nRECOMMENDED READING MATERIAL \n\nA summary of the Occupational Energy Research Program (OERP) studies\n353 NIOSH products about radiation can be found in NIOSHTIC-2\, which is a\nsearchable bibliographic database of occupational safety and health publications\,\nsupported in whole or in part by the National Institute for Occupational Safety and Health\n(NIOSH).\nInternational Dose Effect Alliance (IDEA) Virtual Workshop – December 2\, 2020\nChallenges and Benefits of Repurposing Products for Use during a Radiation Public Health Emergency: Lessons Learned from Biological Threats and other Disease Treatments. Andrea L. DiCarlo\, David R. Cassatt\, William E. Dowling\, John L. Esker\, Judith A. Hewitt\, Oxana Selivanova\, Mark S. Williams and Paul W. Price. Radiation Research 190\, 659–676 (2018); 0033-7587/18. DOI: 10.1667/RR15137.1.\nCutaneous Radiation Injuries: Models\, Assessment and Treatments. Andrea L. DiCarlo\, Aaron C. Bandremer\, Brynn A. Hollingsworth\, Suhail Kasim\, Adebayo Laniyonu\, Nushin F. Todd\, Sue-Jane Wang\, Ellen R. Wertheimer and Carmen I. Rios. Radiation Research 194\, 315–344 (2020); 0033-7587/20. DOI: 10.1667/RADE-20-00120.1.\nMedical Countermeasures against Nuclear Threats: Radionuclide Decorporation Agents. David R. Cassatt\, Joseph M. Kaminski\, Richard J. Hatchett\, Andrea L. DiCarlo\, Jessica M. Benjamin and Bert W. Maidment. Radiation Research 170\, 540–548 (2008); 0033-7587/08.\nMedical Countermeasures for Platelet Regeneration after Radiation Exposure. Report of a Workshop and Guided Discussion. Andrea L. DiCarlo\, Mortimer Poncz\, David R. Cassatt\, Jui R. Shah\, Christine W. Czarniecki and Bert W. Maidment. Radiation Research 176\, e0001–e0015 (2011); 0033-7587/11. DOI: 10.1667/RROL01.1.\nMedical Countermeasures for Radiation Combined Injury: Radiation with Burn\, Blast\, Trauma and/or Sepsis. Andrea L. DiCarlo\, Richard J. Hatchett\, Joseph M. Kaminski\, G. David Ledney\, Terry C. Pellmar\, Paul Okunieff and Narayani Ramakrishnan. Radiation Research 169\, 712–721 (2008); 0033-7587/08.\nNeutron Radiobiology and Dosimetry. Daniela L. Stricklin\, Jama VanHorne-Sealy\, Carmen I. Rios\, Lisa A. Scott Carnell and Lanyn P. Taliaferro. Radiation Research 195\, 480–496 (2021); 0033-7587/21. DOI: 10.1667/RADE-20-00213.1.\nUse of Growth Factors and Other Cytokines for Treatment of Injuries During a Radiation Public Health Emergency. Andrea L. DiCarlo\, Zulmarie Perez Horta\, Jennifer T. Aldrich\, Ann A. Jakubowski\, William K. Skinner and Cullen M. Case\, Jr. Radiation Research 192\, 99–120 (2019); 0033-7587/19. DOI: 10.1667/RR15363.1.\n\nSPEAKER BIOGRAPHIES \nArmin Ansari is the Radiological Assessment Team Lead at the Centers for Disease Control and Prevention (CDC). He received his B.S. and PhD degrees in radiation biophysics from the University of Kansas and completed his postdoctoral research in radiation mutagenesis at Oak Ridge and Los Alamos National Laboratories. His focus since joining CDC in 2002 has been on public health preparedness and response planning for nuclear and radiological emergencies and he has led the development of key national guidance documents as well as numerous training programs directed at public health professionals. He is a fellow and past president of the Health Physics Society and is certified in comprehensive practice by the American Board of Health Physics. He is also an elected member of the National Council on Radiation Protection and Measurements\, and serves as member of the United States delegation to the United Nations Scientific Committee on the Effects of Atomic Radiation. \nAmy Berrington de González\, D.Phil.\, is the Branch Chief of the NCI’s Radiation Epidemiology Branch. She is an internationally recognized expert in the potential cancer risks from medical radiation exposures. Dr. Berrington is co-PI of the UK Pediatric CT scans cohort\, which was the first epidemiological study to suggest a direct link between CT scans and subsequent cancer risk. She also leads studies on the risk of second cancer after proton therapy and other emerging radiotherapy techniques. Dr. Berrington is currently a member of the NAS Nuclear\nand Radiation Studies Board and has participated in many national and international radiation committees. She is an elected member of the American Epidemiological Society and served on the editorial board for the American Journal of Epidemiology. Before joining the NCI in 2008 she held faculty positions at Oxford and Johns Hopkins University. She has a DPhil in Cancer Epidemiology from the University of Oxford. \nC. Norman Coleman\, MD is the Associate Director for the Radiation Research Program in the Division of Cancer Treatment and Diagnosis and a Senior Investigator in the Radiation Oncology Branch in the Center for Cancer Research\, National Cancer Institute\, NIH. He is also a Senior Medical Advisor in the Office of the Assistant Secretary for Preparedness and Response in the US. Department of Health and Human Services. He received his BA in Mathematics ( University of Vermont)\, MD (Yale University School) and is Board Certified in internal medicine (UC San Francisco)\, medical oncology (NCI) and radiation oncology (Stanford). He served in the US Public Health Service (O-4). Dr Coleman became a tenured faculty member in Radiology and Medicine at Stanford (1978 – 1985) and then moved to Harvard Medical School (1985 – 1999) as the Alvan T. and Viola D. Fuller- Medicine Cancer Society Professor and Chairman of the Joint Center for Radiation Therapy. He returned to the NCI in 1999. His interests include an ongoing NCI laboratory program in radiation-inducible molecular targets (using radiation “as a drug”)\, radiation biomarkers of normal tissue injury and multi-modality cancer therapy. His honors include: Gold Medal\, ASTRO (2005)\, Service to America Homeland Security Medal (2011)\, Radiation Research Society Failla Award (2016)\, University of Vermont\, Doctor of Science Honoris Causa (2015) and National Coalition for Cancer Survivorship Ellen Lewis Stovall Patient Centered Cancer Care Award (2018). \nDr. Donald A. Cool\, Ph.D.\, is currently the Technical Executive for Radiation Safety with the Electric Power Research Institute (EPRI). He joined EPRI in 2015 following retirement from the U.S. Nuclear Regulatory Commission\, where he served more than 32 years. Dr. Cool received his B.S. degree in Biology from Houghton College. His Masters and Doctorate degrees are in Radiation Biology from the University of Rochester\, School of Medicine and Dentistry. He is the Vice-Chair of the Main Commission of the International Commission on Radiological Protection. He is a Council Member of the U.S. National Council on Radiation Protection and\nMeasurements and was the Co-Chair of NCRP Council Committee 1 which produced NCRP Report 180\, Management of Exposure to Ionizing Radiation: Radiation Protection Guidance for the United States. He has served on numerous panels and expert groups of the International Atomic Energy Agency and Nuclear Energy Agency. He is a Fellow of the Health Physics Society. \nDr. Sylvain Costes is the Branch Chief for the Space Biosciences Research Branch at NASA Ames research center and a senior research scientist leading the Ames radiation biophysics laboratory. He obtained his Ph.D. in the Nuclear Engineering Department at the University of California\, Berkeley\, where he studied radiation biology. Dr. Costes has spent his career leading multidisciplinary research teams in both academic and government scientific institutions. As a staff scientist at the Lawrence Berkeley National Lab\, he was modeling risk for the NASA Human\nresearch program and developing biomarkers for the DOE low dose program. He is now the project manager for Open Science at NASA Biology and Physical Science Division\, where he leads the systems biology research\, AI/ML modeling effort and the software development for two large NASA data systems: the GeneLab Omics repository and the ALSDA repository for physiological data from spaceflight relevant experiments. \nAndrea DiCarlo earned her doctorate from the University of Maryland\, for work focused on targeting heat shock proteins to reduce oxidative stress caused by ionizing radiation exposures and other stressors. These studies led her to carry out post-doctoral work at The Catholic University of America (CUA)\, where she studied radioprotection of normal tissues in animal models of cancer. While at CUA\, Andrea initiated collaborations with staff from the Armed Forces Radiobiology Research Institute (AFRRI) as well as the Georgetown Lombardi Comprehensive Cancer Center\, and parlayed her postdoctoral work into a position as the Project Manager of the\nlaboratory\, and as a CUA faculty member. In 2004\, Andrea became a Program Officer in the Radiation and Nuclear Countermeasures Program (RNCP) at the National Institute of Allergy and Infectious Diseases (NIAID)\, within the National Institutes of Health (NIH)\, where she was responsible for the oversight and management of a research portfolio exceeding ~$20 million dollars per year. She has published extensively in government reports and peer-reviewed journals on the biological effects of radiation exposure\, testing of medical countermeasures\, and evaluation of biodosimetry devices and biomarkers for triage. Representing NIAID\, she has worked with other US government agencies and non-governmental organizations to highlight and support national and international research activities\, reviewed grant applications and manuscripts\, and has served as a subject matter expert and invited presenter for numerous research working groups and conferences. She was named Director of the RNCP in 2019. \nShona “Robin” Elgart is the Space Radiation Element Scientist for the NASA Human Research Program. Dr. Elgart has more than 20 years of research experience across multiple life-science disciplines\, including medical physics and radiation biology. She received a Bachelor’s degree in microbiology from the University of California at Santa Barbara and a Master’s and Doctorate in biomedical physics from the University of California at Los Angeles in the laboratory of Dr. Keisuke Iwamoto. Her dissertation focused on characterizing the DNA damage response following low-dose radiological exams in patient samples. Before joining The Space Radiation Element in April 2020\, Dr. Elgart served as a subject matter expert specializing in space radiation health risks for NASA’s Space Radiation Analysis Group (SRAG) where she directed and managed reviews of radiation health outcome evidence\, translated research findings into evidence-based operational radiation protection strategies\, and analyzed astronaut exposure and risk for the Radiation Health Office. She also has four years of mission operations experience as a Space Environment Officer and Radiation Mission Manager for Mission Control\nCenter in Houston. As the Element Scientist for the Space Radiation Element\, Dr. Elgart’s primary objective is to develop and execute a robust applied research strategy to meet the agency’s goal to put the first woman on the Moon and the first humans on Mars. \nJacqueline Garnier-Laplace is Deputy Head of the Division of Radiological Protection and Human Aspects of Nuclear Safety at the OECD Nuclear Energy Agency (NEA). She joined the Agency in May 2019. She serves as the Scientific Secretary for the Committee on Radiological Protection and Public Health (CRPPH)\, and a number of subsidiary groups such as the HighLevel Group on Low Dose Research. Previously\, she was the Deputy Director in charge of Research for Radiological Protection at the French Institute for radiological protection and nuclear safety (IRSN). During her 28-year career in the field of radiological protection\, she held various manager positions e.g.\, Deputy Director of the Environment (2015-2017)\, Head of Department on Research and Expertise on Environmental Risks (2007-2015). She is a member of the International Commission on Radiological Protection (ICRP). After being the scientific secretary of Committee 1 on “Effects of ionising radiation” for the period 2017-2021\, she is now serving Committee 4 on “Application of the Commission’s recommendations” until 2025. She\nhas (co)-authored ca. 110 peer-reviewed papers mainly dealing with various radiological\nprotection scientific issues. \nDr. Arthur M. Katz spent almost 40 years in the U.S. Department of Energy and predecessor agencies dealing with a wide range of energy and science topics including advanced nuclear reactors\, planning and international collaboration in fusion energy\, and fundamental biological and environmental research. In the Office of Biological and Environmental Research (OBER) he was responsible for managing projects that were part of DOE’s contribution to the Human Genome Program\, research into low dose radiation health effects\, and a variety of molecular imaging and structural biology projects. He was a member of the Low Dose Radiation Expert Subcommittee reporting to the Biological and Environmental Research Advisory Committee on Low Dose Radiation research. He received a PhD in chemistry from the University of Rochester\, 1969 and a M.S. in meteorology from MIT\, 1974. \nKaitlin Kelly-Reif is an epidemiologist in the NIOSH Division of Field Studies and Engineering\, Field Research Branch. She earned her masters and PhD in environmental and occupational epidemiology from the Gillings School of Global Public Health\, University of North Carolina Chapel Hill where she studied cancer among underground uranium miners in the Czech Republic. In 2014 she was a US National Science Foundation fellow at the Radiation Effects Research Foundation in Hiroshima\, Japan. Dr. Kelly-Reif leads chronic disease studies of workers exposed to ionizing radiation\, particulate matter\, and industrial chemicals. At NIOSH Dr. Kelly-Reif leads two large and historically important studies of radiation-exposed workers\, the US Colorado Plateau uranium miners’ study and the pooled US Nuclear Workers study. She also represents NIOSH in two international research consortia\, the Pooled Uranium Miners Analysis (PUMA) and the International Nuclear Workers Study (INWORKS). \nDominique Laurier\, PhD\, is the head of a research department on the biological and health effects of low-dose radiation exposure at the French Institute for Radiation Protection and Nuclear Safety (IRSN). He has 25 years of experience in the field of radiation epidemiology and has participated in numerous national and international research projects on the health effects of low-dose radiation exposure. He has been Chair of the Nuclear Energy Agency’s (NEA) High Level Group on Low Dose Research (HLG-LDR) since 2020. He has been a member of the main commission of the International Commission on Radiological Protection (ICRP) since 2017 and is currently the chairman of ICRP Committee 1\, as well as the French representative to the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). \nAlexandra C. Miller\, PhD.\, is a senior scientist and research biologist in the Science Research Department (SRD) at the Armed Forces Radiobiology Research Institute (AFRRI) at the Uniformed Services University of the Health Sciences (USUHS). Dr. Miller is an internationally recognized researcher in the field of depleted uranium toxicity and late radiation biological effects. She is the AFRRI/SRD program leader of the chronic low dose radiation program otherwise known as the Combat Operations at Low Dose research program (COAL-R) at AFRRI. Dr. Miller is a trained radiation biologist educated at the State University of NY at Buffalo in the Roswell Park Cancer Division. Dr. Miller has over 74 publications\, 1 book on Depleted uranium\, and multiple book chapters on low dose radiation and uranium metal toxicity. She holds adjunct or visiting scientist positions at USUHS Department of Radiology and Radiation Science\, Columbia University Center for Radiological Research NY\, NYU Langone Medical Center\, and the Department of Chemistry and Life Science at US Military Academy West Point. A long-time AFRRI scientist\, Dr. Miller has publications in the areas of radiation biochemistry\, radiation protection\, radiation mechanisms\, military medicine\, depleted uranium and heavy metal biological effects. Currently she leads funded-studies on low dose mixed field neutron effects\, radiation cardiotoxicity\, radiation countermeasure development\, and use of 3-D models to assess low dose neurological responses. Dr. Miller serves as the lead AFRRI member of the NATO Science and Technology Organizations (STO) Working Group on Radiation BioeffectsT RTG291 and was recently invited to serve as a Department of Defense member of the ICCVAM – Consideration of Alternate Methods Working Group.
URL:https://globalbiodefense.com/event/developing-a-long-term-strategy-for-low-dose-radiation-research-in-the-u-s/
CATEGORIES:Conference
LOCATION:https://www.nationalacademies.org/event/09-24-2021/developing-a-long-term-strategy-for-low-dose-radiation-research-in-the-united-states-meeting-4-september-24-2021
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20210925T080000
DTEND;TZID=America/Los_Angeles:20210925T170000
DTSTAMP:20210925T162800Z
CREATED:20210925T162800Z
LAST-MODIFIED:20210925T162800Z
UID:49841-1632556800-1632589200@globalbiodefense.com
SUMMARY:ABRCMS 2021 - Annual Biomedical Research Conference for Minority Students
DESCRIPTION:The Annual Biomedical Research Conference for Minority Students (ABRCMS)\, recipient of the 2019 AIMBE Excellence in STEM Education Award\, is one of the largest communities of underrepresented minorities in science\, technology\, engineering and mathematics. Students attend this conference to present their research\, enhance professional development skills\, explore graduate schools\, and network. Research faculty and program directors play an essential role in mentoring students and learning strategies for facilitating student success. \nLast year\, ABRCMS engaged nearly 4000 attendees through scientific and professional development sessions\, student presentations and networking opportunities. This year\, ABRCMS: The Virtual Experience will deliver timely and relevant content and activities tailored to the current times. You can expect the same ABRCMS conference you have come to love – with opportunities to learn\, share and connect with peers and experts – in a socially distant format. \nPlease visit the ABRCMS 2021 website for more information.
URL:https://globalbiodefense.com/event/abrcms-2021-annual-biomedical-research-conference-for-minority-students/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210927T120000
DTEND;TZID=America/New_York:20210927T140000
DTSTAMP:20210924T003101Z
CREATED:20210906T002704Z
LAST-MODIFIED:20210924T003101Z
UID:49752-1632744000-1632751200@globalbiodefense.com
SUMMARY:Evolving Crisis Standards of Care and Ongoing Lessons from COVID-19
DESCRIPTION:COVID-19 has fundamentally challenged the delivery of health care services worldwide\, forcing difficult choices on health professionals and laying bare many preexisting health\, medical\, and public health sector frailties. This National Academies workshop series will re-explore previous IOM Crisis Standards of Care recommendations in light of ongoing lessons from the COVID-19 pandemic\, with a particular focus on disaster planning\, legal and equity considerations\, and staffing considerations. \nIn the first virtual workshop of the series\, expert panelists will specifically: \n\nRe-examine the definitions and recommendations first outlined in IOM’s 2009 “Guidance for Establishing Crisis Standards of Care for Use in Disaster Situations: A Letter Report”\nRe-explore the framework described in IOM’s 2012 report “Crisis Standards of Care: A Systems Framework for Catastrophic Disaster Response”\nReflect on pre-COVID-19 “lessons learned”\, and discuss which have been confirmed and/or refuted by the ongoing COVID-19 crisis.\nReflect on the strengths and weaknesses of the CSC framework and activation/implementation guidance in light of our current experiences and challenges with COVID-19.\n\nConfirmed speakers include: \n\nMonica Peek\, MD\, MPH\, Professor of Medicine\, University of Chicago Medicine\nJennifer Piatt\, Deputy Director with the Network for Public Health Law’s Western Region Office\nMike Wargo\, VP for Preparedness & Emergency Operations\, HCA Healthcare’s enterprise\nAnuj Mehta MD\, MD\, Assistant Professor\, University of Colorado\nDan Hanfling\, MD\, Vice President\, Technical Staff\, In-Q-Tel\nCraig Vanderwagen\, MD\, Rear Admiral USPHS – retired\, founding Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services\, and Founder and General Manager of East West Protection\, LLC\n\nPlease visit the National Academies’ Evolving Crisis Standards of Care and Ongoing Lessons from COVID-19 event website for more information.
URL:https://globalbiodefense.com/event/evolving-crisis-standards-of-care-and-ongoing-lessons-from-covid-19/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210927T123000
DTEND;TZID=America/New_York:20210927T163000
DTSTAMP:20240623T230830Z
CREATED:20210916T000655Z
LAST-MODIFIED:20240623T230830Z
UID:49750-1632745800-1632760200@globalbiodefense.com
SUMMARY:NASEM Committee on Toxicology Annual Meeting
DESCRIPTION:The National Acadamies’ Committee on Toxicology (COT) is a standing committee established in 1947 to provide independent\, authoritative scientific advice to the U.S. military and other agencies on environmental and occupational health questions. Under a contract with the Department of Defense (DOD)\, COT provides advice on toxicological matters by evaluating hazards and health implications of specific product uses and recommending tolerable or emergency exposure guidance levels for chemicals under specific conditions. \nCOT meets at least once a year to review the progress of its committees addressing the tasks assigned by DOD. It also communicates through various other means with representatives of DOD and other agencies to keep abreast of developing requirements and problems\, emerging issues\, and newly initiated research and technology. \nThe committee will discuss whether there may be a need to update any Exposure Guideline Levels because of new toxicological data or understandings\, or to address women’s greater military participation. The committee will overview of the state-of-the science on effects\, levels at which they occur\, animal models\, mechanisms\, and potential for complicating co-exposures. The presentation and discussion will lay the groundwork for potential future conversations with DOD about occupational limit setting. \n\nExposure Guideline Levels: Needs for Updates?\nShort Talk: Submarine Environment Perspective on Women of Child-Bearing Age\nStudy Update: Guidance on PFAS Testing and Health Outcomes\nDiscussion: Toxicology Needs and Challenges at Department of Defense\n\nPlease visit the 2021 Committee on Toxicology Annual Meeting website for more information.
URL:https://globalbiodefense.com/event/nasem-committee-on-toxicology-annual-meeting/
CATEGORIES:Conference
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210927T200000
DTEND;TZID=America/New_York:20210927T220000
DTSTAMP:20210924T000415Z
CREATED:20210902T000135Z
LAST-MODIFIED:20210924T000415Z
UID:49748-1632772800-1632780000@globalbiodefense.com
SUMMARY:Addressing Inaccurate and Misleading Information about Biological Threats through Scientific Collaboration and Communication
DESCRIPTION:The intentional or unintentional spread of inaccurate and misleading information during infectious disease outbreaks has become commonplace. Such campaigns can undermine outbreak response activities in affected areas and discredit national\, regional\, and international leaders in biosecurity and health security from a variety of countries and international organizations. The U.S. National Academies of Sciences\, Engineering\, and Medicine convened a committee of experts from the United States and Southeast Asia to serve on a study committee that will analyze how scientists can determine which claims may be addressed by defensible scientific information and how scientists can work together to address those claims. The study will result in a strategy for developing an international network of scientists to address inaccurate and misleading claims. \nThe meeting is intended to focus on determining how to engage scientists in a trusted network to build a defensible\, accurate scientific knowledge-base that could be used to counter false claims\, and developing a guide to help scientists identify and address such claims. This meeting\, any input provided\, and any discussions are designed to benefit Central and Southeast Asia. U.S. participants of the meeting should plan to provide needed input to support the overarching goal of the study to benefit the region. \nThe registration deadline has passed for this open session meeting on September 27\, 2021 from 8:00 – 10:00 PM ET. Please contact both Dr. Kavita Berger (KBerger@nas.edu) and Dr. Jenell Walsh-Thomas (JWalsh-Thomas@nas.edu) if you have any questions about this meeting.
URL:https://globalbiodefense.com/event/addressing-inaccurate-and-misleading-information-about-biological-threats-through-scientific-collaboration-and-communication/
CATEGORIES:Conference
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210928
DTEND;VALUE=DATE:20210929
DTSTAMP:20210925T172033Z
CREATED:20210925T171954Z
LAST-MODIFIED:20210925T172033Z
UID:49851-1632787200-1632873599@globalbiodefense.com
SUMMARY:World Rabies Day
DESCRIPTION:World Rabies Day is observed annually to raise awareness about rabies prevention and to highlight progress in defeating this horrifying disease. \nEstablished in 2007\, it aims to raise awareness about rabies and help the world come together to fight this highly fatal\, neglected disease. The theme for 2021 is ‘Rabies: Facts\, not Fear\,’ focusing on: \n\nThe knowledge\, strategies\, and tools to eliminate dog-mediated rabies.\nSuccessful approaches and tools to prevent\, control and eliminate the disease.\nSaving lives by spreading awareness about rabies\, and teaching others how to prevent it.\n\n28 September also marks the anniversary of Louis Pasteur’s death\, the French chemist and microbiologist\, who developed the first rabies vaccine. \nRabies is estimated to cause 59\,000 human deaths annually in over 150 countries\, with 95% of cases occurring in Africa and Asia. Due to underreporting and uncertain estimates\, this number is likely a gross underestimate. The burden of disease is disproportionally borne by rural poor populations\, with approximately half of cases attributable to children under 15 years of age. \nToday\, safe and efficacious animal and human vaccines are among the important tools that exist to eliminate human deaths from rabies while awareness is the key driver for success of communities to engage in effective rabies prevention. \nIn the United States\, rabies deaths are very rare thanks to successful animal control and vaccination programs\, and a robust healthcare structure that can provide vaccines to people shortly after an exposure. About 55\,000 Americans get postexposure prophylaxis (PEP) each year to prevent rabies infection after being bitten or scratched by an infected or suspected infected animal. \nRabies is a viral zoonotic disease that causes progressive and fatal inflammation of the brain and spinal cord. Clinically\, it has two forms: \nFurious rabies – characterized by hyperactivity and hallucinations.\nParalytic rabies – characterized by paralysis and coma. \nAlthough fatal once clinical signs appear\, rabies is entirely avoidable; vaccines\, medicines and technologies have long been available to prevent death from rabies. Nevertheless\, rabies still kills tens of thousands of people each year. Of these cases\, approximately 99% are acquired from the bite of an infected dog. \nDog-mediated human rabies can be eliminated by tackling the disease at its source: infected dogs. Making people aware of how to avoid the bites of rabid dogs\, to seek treatment when bitten and to vaccinate animals can successfully disrupt the rabies transmission cycle. \nEarly symptoms of a rabies infection can include a fever with pain and unusual or unexplained tingling\, pricking or burning sensation (paraesthesia) at the wound site. In later states\, the virus spreads to the central nervous system\, causing fatal inflammation of the brain and spinal cord. The incubation period of the disease can vary from 1 week to 1 year\, though it is typically 2–3 months. \nThe two types of rabies show different symptoms. Furious rabies causes signs of hyperactivity\, excitable behaviour\, hydrophobia (fear of water) and sometimes aerophobia (fear of drafts or of fresh air). Death occurs after a few days due to cardio-respiratory arrest. \nParalytic rabies\, which accounts for about 20% of the total number of human cases\, runs a less dramatic and usually longer course than the furious form. Muscles gradually become paralysed\, starting at the site of the bite or scratch. A coma slowly develops and eventually death occurs. The paralytic form of rabies is often misdiagnosed\, contributing to the under-reporting of the disease. \nLearn more about Rabies at the World Health Organization website. \n 
URL:https://globalbiodefense.com/event/world-rabies-day/
LOCATION:Global Biodefense Calendar
CATEGORIES:Awareness Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210928T090000
DTEND;TZID=America/New_York:20210928T103000
DTSTAMP:20210925T165652Z
CREATED:20210925T165502Z
LAST-MODIFIED:20210925T165652Z
UID:49848-1632819600-1632825000@globalbiodefense.com
SUMMARY:Launch of the Defeating Meningitis by 2030 Roadmap
DESCRIPTION:The impact of meningitis is as profound as it is diverse: it can kill within hours\, disrupts health\nsystems\, impedes education and child development\, devastates families and communities\, and causes\nlifelong disabilities. Meningitis epidemics are unpredictable and can strike anywhere\, affecting people\nof any age\, including healthy children and young adults. \nDespite successful efforts to control meningitis in several regions\, meningitis continues to be a major public health issue. It kills about 250 000 people annually\, and leaves 1 in 5 of those affected with long-term devastating sequelae. \nDr Tedros Adhanom Ghebreyesus\, Director-General of the World Health Organization and partners will be launching Defeating Meningitis by 2030: A Global Road Map on: Tuesday\, 28 September 2021.   \nThe meningitis road map—developed though a robust\, multidisciplinary consultation process—\nrepresents an unprecedented opportunity to channel the wave of “defeat meningitis” momentum\ninto a concrete plan of action. Defeating meningitis is not only feasible\, but also critical to the\nachievement of the Sustainable Development Goals (SDGs) and will strengthen many aspects of the\nhealth system – from disease surveillance\, to immunization\, to primary health care and universal\nhealth coverage\, to improving services for persons living with disabilities. \nImplementing the road map is how the global community will come together to defeat meningitis. The five pillars of the road map each address a critical need in the fight against meningitis: prevention and epidemic control\, prompt diagnosis and treatment\, disease surveillance\, support and care for people (and families) affected by meningitis\, and advocacy and engagement. How do we leverage the road map to facilitate impact? This panel will share some of the major strides we have already made and provide a view on what the future holds. \nPlease visit the WHO’s Launch of the Defeating Meningitis Roadmap website for more information
URL:https://globalbiodefense.com/event/launch-of-the-defeating-meningitis-by-2030-roadmap/
CATEGORIES:Awareness Event,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/09/world-health-defeating-meningitis-global-road-map.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210928T110000
DTEND;TZID=America/New_York:20210928T130000
DTSTAMP:20210925T183006Z
CREATED:20210915T181953Z
LAST-MODIFIED:20210925T183006Z
UID:49861-1632826800-1632834000@globalbiodefense.com
SUMMARY:National Biodefense Science Board Public Meeting
DESCRIPTION:The National Biodefense Science Board (NBSB) will convene to discuss the strategy and planning for the National Special Pathogen System and other high priority issues related to national public health emergency preparedness and response. \nThe meeting is open to the public and will be held in a virtual format on September 28\, 2021. The NBSB invites those who are involved in or represent a relevant industry\, academia\, health profession\, health care consumer organization\, or state\, Tribal\, territorial or local government to request up to seven minutes to address the board in person via Zoom. \nRequests to provide remarks to the NBSB during the public meeting may be sent to NBSB@hhs.gov. Please include the name of the speaker\, organization\, and a full explanation of the intended comments. Please submit your request by 5PM ET on September 24\, 2021. \nABOUT THE NBSB \nThe National Biodefense Science Board (NBSB or the Board) is authorized under Section 319M of the Public Health Service (PHS) Act\, as added by Section 402 of the Pandemic and All-Hazards Preparedness Act of 2006 and amended by Section 404 of the Pandemic and All-Hazards Preparedness Reauthorization Act. The Board is governed by the Federal Advisory Committee Act\, which sets forth standards for the formation and use of advisory committees. The NBSB provides expert advice and guidance on scientific\, technical\, and other matters of special interest to the Department regarding current and future chemical\, biological\, nuclear\, and radiological agents\, whether naturally occurring\, accidental\, or deliberate. \nMembers of the public may attend the meeting via a toll-free phone number or Zoom teleconference\, which requires pre-registration. The meeting link to pre-register will be posted on https://www.phe.gov/​nbsb. Members of the public may provide written comments or submit questions for consideration by the NBSB at any time via email to NBSB@hhs.gov. Members of the public are also encouraged to provide comments after the meeting.
URL:https://globalbiodefense.com/event/national-biodefense-science-board-public-meeting-2/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20210930
DTSTAMP:20210919T003055Z
CREATED:20210919T003055Z
LAST-MODIFIED:20210919T003055Z
UID:49670-1632873600-1632959999@globalbiodefense.com
SUMMARY:TEI-REX Proposer's Day
DESCRIPTION:The Intelligence Advanced Research Projects Activity (IARPA) will hold a virtual Proposers’ Day for the TEI-REX Program (Targeted Evaluation of Ionizing Radiation Exposure) on September 29\, 2021 from 10:00 am to 5:00 pm EDT with potential overflow into September 30\, 2021 from 10:00 am to 1:00 pm. \nThe TEI-REX Proposers’ Day meeting will be used to introduce the research requirements to potential performers and provide information on program objectives. The TEI-REX Program aims to establish novel biodosimetry approaches enabling improved quantification of low-dose ionizing radiation exposures (<0.75 Gray) from minimally and non-invasive samples\, while also expanding quantitative and qualitative knowledge of the exposure environment. \nIARPA holds Proposers’ Days to provide information to assist potential proposers to evaluate whether and how they might respond to the Government’s research and development solicitations and to increase efficiency in proposal preparation and evaluation. The TEI-REX Proposers’ Day is open only to registered potential proposers\, and not to the media or the general public. \nThe meeting will be held entirely on the WebEx video conference platform\, and a recorded video of the meeting will be made available to the public on the IARPA website. \nPre-registration is required and closes on September 24\, 2021 at 5:00 pm EDT. \nOpportunities to facilitate teaming are available to registrants for the TEI-REX Proposers’ Day. IARPA highly encourages potential proposers to establish strong teams capable of addressing the technical challenges TEI-REX aims to overcome. \nThis meeting will include an introduction to IARPA\, an overview of the program\, technical challenges\, and expected participation requirements. Before the Proposers’ Day meeting\, attendees may submit comments or questions regarding TEI-REX by emailing the program manager (contact information at the event link).
URL:https://globalbiodefense.com/event/tei-rex-proposers-day/
CATEGORIES:Government Hosted,Industry Day
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211001
DTSTAMP:20210923T222435Z
CREATED:20210923T222435Z
LAST-MODIFIED:20210923T222435Z
UID:49739-1632873600-1633046399@globalbiodefense.com
SUMMARY:Medical Biomedical Biodefense: Support to the Warfighter Virtual Symposium
DESCRIPTION:The Medical\, Biomedical & Biodefense: Support to the Warfighter Virtual Symposium will be held 29-30 September 2021. \nThe Fort Bragg Research Institute will host senior medical leaders from Fort Bragg for a discussion on near-term medical requirements for operations in contested battlespace and the health care vision for the next-generation warfighter. \nA panel of experts will bring key insights gleaned from the role they or their organization played over the last year of responding to the COVID-19 pandemic and explore the ways government agencies\, companies and non-profit organizations can all play a critical role in preparing us for the future. \nPanel presenters will identify requirements of VA medical centers and clinics in the region for medical products and services\, including research and development\, supplies\, equipment\, devices\, pharmaceuticals\, training\, IT and staff augmentation. \nHuman Performance Optimization Advanced Technology Showcase (HPO ATS) \nAs part of the MBB Symposium\, the North Carolina Defense Technology Transition Office (DEFTECH) and the NC Center for Optimizing Military Performance (NC-COMP) will conduct an HPO Advanced Technology Showcase. DEFTECH will release a “Request for Technologies – RFT” addressing a broad range of HPO R&D areas. \nHOSTED BY: \n\nOffice of United States Senator Richard Burr\nOffice of United States Senator Thom Tillis\nNorth Carolina Military Business Center\nNorth Carolina Biotechnology Center\nUNC System\n\nSYMPOSIUM PARTNERS. \n\nNorth Carolina Defense Technology Transition Office (DEFTECH)\nNorth Carolina Center for Optimizing Military Performance (NC-COMP)\nDefense Alliance of North Carolina\n\nLEARN MORE: https://mbb.ncmbc.us/event-info/
URL:https://globalbiodefense.com/event/medical-biomedical-biodefense-support-to-the-warfighter-virtual-symposium/
CATEGORIES:Conference
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211004
DTSTAMP:20210925T051605Z
CREATED:20210925T051605Z
LAST-MODIFIED:20210925T051605Z
UID:49818-1632873600-1633305599@globalbiodefense.com
SUMMARY:IDWeek 2021 - Infectious Diseases Society of America
DESCRIPTION:IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA)\, Society for Healthcare Epidemiology of America (SHEA)\, the HIV Medicine Association (HIVMA)\, the Pediatric Infectious Diseases Society (PIDS)\, and the Society of Infectious Diseases Pharmacists (SIDP). \nIDWeek 2021 takes place virtually from Sept. 29-Oct. 3. IDWeek and its partners will again be joined with other scientific agencies\, non-governmental agencies\, and infectious diseases organizations around the world. Each will bring unique global perspectives and updated information on various aspects of COVID-19. \nHighlighted presentations and panels include: \n\nA Day with the Stewardship Pager – Challenging Stewardship Cases\nGenomics for Emerging (Zoonotic) viral diseases\nPicornaviruses: Beyond Hand\, Foot and Mouth Disease\nResuscitating Antimicrobial Stewardship and Healthcare Epidemiology Post-COVID\nChallenging Cases In Travel & Tropical Medicine\nSay It Don’t Spray It: Examining the Perspectives on Aerosols and Virus Transmission\nThe Tiny but Fierce Beasts of COVID-19 & Healthcare Epidemiology – Controversies in Pediatric Infection Prevention\nWhat’s Hot in Innovative Microbiological Diagnostics\nOptimizing Molecular Testing in Algorithms for the Diagnosis of Challenging Fungal Pathogens\nUnwanted guests: when fungi complicate patient care\nPCRs\, Presenteeism and PPE: Infection Prevention Post-COVID\nPotpourri: the vaccines I did not hear about during the pandemic\nTackling Antibiotic Resistance and Healthcare-associated Infections Around the Globe: Prevention and Surveillance Strategies\nInfectious Disease Consulting for Businesses During COVID-19: Tales from the Front Line\nA Day with the Hospital Epidemiologist’s Pager: Challenging Cases in Infection Prevention\nClimate Change\, Environmental Degradation and Infectious Diseases\nHomelessness and Infectious Diseases\nUpdates on Malaria Globally\nBurnout in Healthcare Epidemiology\nInfluencing Antibiotic Stewardship Activities—The Devil is in the Details\n\nPlease visit the IDWeek 2021 website for more information.
URL:https://globalbiodefense.com/event/idweek-2021-infectious-diseases-society-of-america/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210929T080000
DTEND;TZID=America/New_York:20210929T100000
DTSTAMP:20210925T153645Z
CREATED:20210911T152019Z
LAST-MODIFIED:20210925T153645Z
UID:49822-1632902400-1632909600@globalbiodefense.com
SUMMARY:Safeguarding and Advancing SRHR in Universal Health Coverage: On the Road to the 2023 UN High-Level Meeting on UHC
DESCRIPTION:Anti-gender movements and the COVID-19 pandemic have deepened existing challenges to realizing sexual and reproductive health and rights (SRHR). Universal health coverage can help overcome these barriers\, but only with an intersectional lens that centers girls and women in all their identities. The discussion will highlight why strengthened prioritization of SRHR must happen now\, as the foundation is being laid for the 2023 UN High-Level Meeting on Universal Health Coverage. \nThis is a virtual UNGA 76 side event hosted by the Alliance for Gender Equality and UHC \nInterpretation in English\, French\, and Spanish; auto closed-captioning in English. \nMichelle Remme (Moderator)\nDeputy Director @United Nations University International Institute for Global Health\n@DrMichelleRemme Dr. Michelle Remme (she/her) is Deputy Director at the United Nations University International Institute for Global Health\, where she leads the Gender and Health Hub. She is a health economist with over fifteen years of experience as a researcher and policy advisor in global health\, having worked in academia\, the UN system\, donor development cooperation and private consulting. Prior to joining UNU\, she served as Assistant Professor in Health Economics at the London School of Hygiene and Tropical Medicine. She conducts research and provides policy advice on topics related to the economics and financing of health programmes\, health systems and gender-responsive health interventions. \nHelen Clark\nFormer Prime Minister of New Zealand; Women Deliver Board Member @Women Deliver \n@HelenClarkNZ Helen Clark (she/her) was Prime Minister of New Zealand from 1999–2008. As Prime Minister\, and as a Member of Parliament over 27 years\, Helen engaged widely in policy development and advocacy across the international\, economic\, social\, environmental\, and cultural spheres. She advocated strongly for New Zealand’s comprehensive program on sustainability and for tackling the problems of climate change. She was an active leader of her country’s foreign relations\, engaging in a wide range of international issues. Helen was Administrator of the United Nations Development Programme from 2009-2017\, where she led UNDP to be ranked the most transparent global development organisation. She was also Chair of the United Nations Development Group. Helen continues to be a strong voice for sustainable development\, climate action\, gender equality and women’s leadership\, peace and justice\, and action on non-communicable diseases and on HIV. \nDumiso (Dumi) Gatsha\nFounder/Advisory Group Member @Success Capital Organisation/Civil Society Engagement Mechanism for UHC2030 (CSEM) \n@ProSuccessBW Dumiso (Dumi) Gatsha (they/them) is a proudly Pan African and unequivocally non-binary queer feminist working on eliminating the barriers between grassroots experiences and global policymaking. Dumi is the Founder of Success Capital Organisation\, a queer\, youth\, feminist-led\, managed and serving grassroots organisation working within Botswana’s community health system on HIV\, SRHR\, and GBV responses. In particular\, Dumi campaigns for period dignity\, safe abortion and socioeconomic equity beyond binaries. Dumi has previously consulted with V-Dem Institute\, Botswana Council of NGOs\, UNDP Botswana and CIVICUS World Alliance\, among others. Dumi is an advisory group member of the Civil Society Engagement Mechanism for UHC2030 (CSEM)\, Member of the African Queer Youth Initiative\, International Member Representative of Amnesty International\, and Vice Chair of Gender DynamiX (RSA)\, among other voluntary roles. \nVeloshnee Govender\nScientist\, Department of Sexual and Reproductive Health and Research @World Health Organization (WHO) \n@HRPresearch Veloshnee Govender (she/her) is a health economist with health policy and systems expertise in the Department of Sexual and Reproductive Health and Research (WHO\, Geneva). Veloshnee also holds an honorary senior lecturer post in the Health Economics Unit (University of Cape Town\, South Africa). Prior experiences include the Alliance for Health Policy and Systems Research (WHO\, Geneva)\, Health Economics Unit\, and Indian Institute of Management (Bangalore\, India). Her areas of work include health system strengthening and gender and equity issues in the context of sexual and reproductive health and rights and TB/HIV/AIDS. \nJagadishwor (Jagadish) Ghimire\nDeputy Country Director @Ipas Nepal \n@JagadishGhimre Jagadishwor (Jagadish) Ghimire (he/him) is a Development Practitioner in Nepal with 14+ years of experience in health systems focusing on sexual and reproductive health and rights. Jagadish holds a Master’s in Public Health (MPH) and Master of Arts in Sociology (MA)\, and is currently a MPhil Fellow in Population Studies. Jagadish is the Deputy Country Director for Ipas Nepal\, where he leads the implementation of project activities focusing on SRHR\, gender based violence prevention and response\, and climate justice and SRHR. Jagadish has also worked for UNFPA Nepal as a Family Planning Advisor\, CARE Nepal as Health Program Coordinator focusing on SRHR and GBV\, Family Planning Association of Nepal/IPPF as a Chief of Party for USAID’s Support for international Family Planning Organizations\, and with Population Services International (PSI) Nepal as Head of Program implementation\, among others. \nMilanya T. Jackline\nProgram Officer in charge of Community Empowerment @Kenya Female Advisory Organization (KEFEADO) \n@milanyakipusa Milanya T. Jackline (she/her) is an African feminist and is the Program Officer in charge of Community Empowerment at Kenya Female Advisory Organization (KEFEADO). Milanya is passionate about advocacy for gender equality\, reproductive health and rights\, and economic empowerment\, especially for adolescent girls and young women and including those with disabilities. She has been recognized by the East Africa Young Women Leadership Institute (EAYWLI) and is a trained facilitator on Looking in Looking Out (LILO) Sexual Identity and Human Right and on Sexuality and Spirituality under the Hearts Set of Pilgrimage Kenya Charter. She was part of the team that advocated for quality\, friendly and affordable SRHR health care services for the LGBTIQ in Migori and Kisumu in 2015. \nDr. Guna Nidhi Sharma\nSenior Health Administrator and Policy and Planning Section Chief @Government of Nepal\, Ministry of Health and Population \n@dr_gunish @mohpnep Dr. Guna Nidhi Sharma (he/him) (MPH\, Virije University\, Amsterdam\, the Netherlands\, and MBBS\, Tribhuvan University\, Institute of Medicine\, Maharajgunj Campus) is a Senior Health Administrator and the Policy and Planning Section Chief at the Nepal Ministry of Health and Population. He has engaged in formulation of the National Health Policy 2019\, the 15th Periodic Plan 2019-2023 and the Health Financing Strategy. He is a core technical team member at the ministry to respond COVID-19 pandemic and directly involved in developing more than 50 COVID-related strategic and technical documents. Dr. Guna’s main responsibilities are engaging in development of national level policies\, strategies and plans aligning with constitutional mandate and international commitments such as the SDGs. He has more than 16 years of experience in national and international organizations. Dr. Guna recently received a prestigious national award by the Right Honorable President of Nepal. \nSafeguarding and Advancing SRHR in Universal Health Coverage: On the Road to the 2023 UN High-Level Meeting on UHC \n  \n 
URL:https://globalbiodefense.com/event/safeguarding-and-advancing-srhr-in-universal-health-coverage-on-the-road-to-the-2023-un-high-level-meeting-on-uhc/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:https://globalhealth.org/event/safeguarding-and-advancing-srhr-in-universal-health-coverage-on-the-road-to-the-2023-un-high-level-meeting-on-uhc/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210929T120000
DTEND;TZID=America/New_York:20210929T153000
DTSTAMP:20210924T190915Z
CREATED:20210904T185727Z
LAST-MODIFIED:20210924T190915Z
UID:49763-1632916800-1632929400@globalbiodefense.com
SUMMARY:7th Annual Intelligence Community Academic Research Program
DESCRIPTION:The Intelligence Community Academic Research Symposium (ICARS) is the showcase for unclassified academic research supported by the Intelligence Community. \nThis event provides the opportunity for academic researchers\, advisors\, and members of the IC to exchange ideas and engage with fellow experts from diverse scientific backgrounds. Through integration and cooperation\, the IC Academic Research Symposium encourages innovation and collaboration between academia and the Intelligence Community. \nThis year’s participants and sponsors include: \n\nAir Force Institute of Technology\nFBI visiting scientist program\nIC Postdoctoral Research Fellowship Program\nNational Intelligence University\nNGA Academic Research Program\nThe Program on Extremism at George Washington University\nThe Cybersecurity Manufacturing Innovation Institute\nUK IC Postdoctoral Research Fellowship Programme\nUTSA’s National Security Collaboration Center\n\nHighlighted presentations include: \n\nMultiplex Aptamer Biosensors for the Standoff Detection of Nerve Agents\nMetapopulation Dynamics of Outbreaks and their Management\nImproving the Prediction of Hazardous Material Dispersion in an Urban Environment\nForecasting Dengue in Brazil at High Resolution\nLearning about the Geospatial Spread of Pathogens from their Genomes\nDevelopment of a Machine Learning Model to Predict Causes of Encephalitis\nUranium Isoscapes in Natural Waters: Factors Associated with Uranium Concentrations above 30 μg/Liter?\nAttribution of Explosives and Explosive Precursors\nEarly Detection of Chemical-Induced Temporal Stress Signatures in GMO and Non-GMO Maize\nIdentification of Illegal Manufacturing Activity via Wastewater Markers\nBenchmark Data Development to Classify Damage for Natural Disaster Relief Efforts\nNext Generation Cybersecure Architectures Enable U.S. Manufacturing Innovation\, Resilience\, and Productivity\nDeePRK – Measuring Human Performance of DNN-Assisted Object Search and Detection over North Korea\nAdaptive Infrared Thermal Signature Management\nBuilding an Urban Digital Twin: A Research Agenda\nSemantic Representations for Multi-Viewpoint Multimodal Geolocation\nLocalization and Planning for a UAV/Robot Team in Subterranean Environments\nGravity Portals: Quantum Sensors for Enhanced Border Screening\nLeveraging Environment and Culture to Anticipate Social Unrest with Integrated Model- and Data-Driven Approaches\nOptomechanical Sensing: Why So Sensitive?\nThe Impact of Explanations as Communicative Acts on Belief in a Claim: The Role of Source Reliability\n\nKEYNOTE SPEAKERS \nCatherine Marsh\, Ph.D. / Director\, Intelligence Advanced Research Projects Activity (IARPA)\nDr. Catherine Marsh became director of the Intelligence Advanced Research Projects Activity in November 2019 where she is responsible for investing in high-risk/high-payoff research that has the potential to provide our nation with an overwhelming intelligence advantage. Prior to this assignment\, Dr. Marsh was the chief scientist for the CIA’s Directorate of Science and Technology from 2016-2019\, where she was responsible for ensuring that leading-edge science and technology underlies current and future mission capabilities. Before that\, she served as the dean of the DS&T’s George Methlie School. Her first assignment at IARPA was from 2013-2015 as the deputy\ndirector. Dr. Marsh joined the CIA in 2001 and served in serval capacitates to innovate power solutions for the intelligence community. While in industry\, she led the team that put lithium-ion technology on numerous platforms\, including NASA’s MARS exploration rovers Spirit and Opportunity. Dr. Marsh is a director of the National Intelligence Fellow and member of the DS&T’s distinguished expert cadre. She holds a bachelor’s and doctorate in inorganic and analytic\nchemistry from Brown University \nLTC Thomas Pike\, Ph.D. / National Intelligence University\, IC Educator of the Year Awardee\nLTC Tom Pike is faculty at the National Intelligence University and Technical Director of the Center for Anticipatory Intelligence and Adaptive Influence. He earned his PhD in Computational Social Science from George Mason University. His primary research interest is the collective intelligence of complex systems at the organizational and societal level. He has done research on multi-leveled networks and civil conflict. \nBrian T. Holmes\, Ph.D. / Dean\, National Intelligence University School of Science and Technology Intelligence\nDr. Holmes is the Dean of the School of Science and Technology Intelligence at the National Intelligence University in Bethesda\, MD. The School is the focus for science and technical analytic education\, research and external engagement across the intelligence and national security communities. He joined the University in 2012 to complement the existing members of the School and enable its burgeoning mission. The National Intelligence University was chartered by the Department of Defense in 1962\, and the University’s degrees — the Master of Science of Strategic Intelligence\, the Master of Science and Technology Intelligence\, and the Bachelor of Science in Intelligence — are authorized by Congress. The University is managed by the Defense Intelligence Agency (DIA)\, and receives strategic guidance from the Director of National Intelligence (DNI). From 2012-2016\, Dr. Holmes chaired the Emerging and Disruptive Technology\, Geostrategic Resources and Environment\, and Weapons of Mass Destruction concentrations in the School. He serves as an executive representative to the Scientific and Technical Intelligence Committee under the auspices of the National Intelligence Council\, and directly supports Intelligence Community Directive 204 (National Intelligence Priorities Framework). He primarily focuses his research on dual use technologies\, and the translation of emerging research and development into advanced materials for military systems. From 2016-2017\, Dr. Holmes served as the Associate Dean of the School of Science and Technology Intelligence.
URL:https://globalbiodefense.com/event/7th-annual-intelligence-community-academic-research-program/
CATEGORIES:Conference,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/09/intelligence-community-academic-research-icars.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210930T140000
DTEND;TZID=America/New_York:20210930T150000
DTSTAMP:20210924T031215Z
CREATED:20210903T030749Z
LAST-MODIFIED:20210924T031215Z
UID:49756-1633010400-1633014000@globalbiodefense.com
SUMMARY:Addressing Disaster Workforce Needs During the COVID-19 Pandemic
DESCRIPTION:For the past 18 months\, emergency response personnel have dealt with the strain of the COVID-19 pandemic in addition to the regular onslaught of tornadoes\, hurricanes\, wildfires\, and other hazards. With so many concurrent needs and crises\, how can decision makers provide support to the disaster workforce? What strategies can be used to promote resilience and reduce worker burnout? \nIn this webinar\, panelists from the public health and emergency services sectors will discuss approaches for addressing worker burnout\, promoting individual-level resilience\, and mitigating the impacts of worker shortages as the COVID-19 crisis continues to evolve. \nPanelists \nPhil Ambrose\, Glendale Fire Department \nCurry Mayer\, Seattle Office of Emergency Management \nDavid Miller\, New York City Department of Health and Mental Hygiene \nSue Ann Sarpy\, Principal\, Sarpy and Associates\, LLC \nIn response to the current outbreak of COVID-19\, decision-makers at all levels of government have critical and complex questions that are answerable based on evidence from the social\, behavioral\, and economic sciences (SBE). To connect SBE research with decision-makers who need rapid answers\, the National Academies\, with support from the National Science Foundation and the Alfred P. Sloan Foundation\, has established a network of leading individuals and institutions in SBE fields to provide actionable responses to urgent policy questions. The Societal Experts Action Network (SEAN) consists of experts available to develop evidence-based recommendations to support local\, state\, and national responses. \nPlease visit NASEM’s Addressing Disaster Workforce Needs During the COVID-19 Pandemic meeting page for more information.
URL:https://globalbiodefense.com/event/addressing-disaster-workforce-needs-during-the-covid-19-pandemic/
CATEGORIES:Conference
LOCATION:https://livestream.com/accounts/7036396/events/9837666/player?width=640&height=360&enableInfoAndActivity=true&defaultDrawer=&autoPlay=true&mute=false
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20211003T080000
DTEND;TZID=America/Los_Angeles:20211003T170000
DTSTAMP:20211004T003833Z
CREATED:20211004T003833Z
LAST-MODIFIED:20211004T003833Z
UID:50029-1633248000-1633280400@globalbiodefense.com
SUMMARY:Book Event: To End a Plague: America’s Fight to Defeat AIDS in Africa - Emily Bass
DESCRIPTION:CSIS Global Health Policy Center will host a virtual event featuring Emily Bass\, veteran AIDS activist\, historian and journalist\, and author of  To End a Plague: America’s Fight to Defeat AIDS in Africa on Oct 13 from 1:00 p.m. to 2:00 p.m. EDT. \nShe’ll be joined in conversation by Jennifer Kates\, Senior Vice President and Director of Global Health & HIV Policy at KFF; Chris Collins\, President & CEO at Friends of the Global Fight Against AIDS\, Tuberculosis and Malaria; and Ben Plumley\, Senior Advisor at Bay Area Global Health Alliance & Host of A Shot In The Arm and newly launched Vax Up Podcast. Jeffrey L. Sturchio\, CSIS Global Health Policy Center Senior Associate (Non-resident)\, will moderate the discussion. \nTo End a Plague chronicles the transnational activism\, legislative deal-making and unprecedented political leadership that led to President George W. Bush’s 2003 announcement of a program known as the U. S. President’s Emergency Program for AIDS Relief (PEPFAR). Today\, PEPFAR is America’s most successful long-term pandemic-fighting program. With more than $85 billion invested\, 18.2 million men\, women\, and children treated with antiretroviral therapy\, and more than 50 million people provided HIV prevention services in recent years\, it is also the largest commitment by any nation to address a single disease in history. At a time when the world—and the American government—is grappling with how to fund and fight the global Covid-19 pandemic\, this panel will reflect on the lessons learned from PEPFAR\, the crucial contributions by people living with HIV and their allies\, and the crucial factors behind this program’s improbable and long-standing bipartisan support. \nThis event is made possible by the generous support of the Bill & Melinda Gates Foundation.  \nPlease visit the CSIS Emily Bass Book Event website to register.
URL:https://globalbiodefense.com/event/book-event-to-end-a-plague-americas-fight-to-defeat-aids-in-africa-emily-bass/
CATEGORIES:Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=JVE7UZkoO6U
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211005
DTEND;VALUE=DATE:20211007
DTSTAMP:20210924T004748Z
CREATED:20210924T004748Z
LAST-MODIFIED:20210924T004748Z
UID:49754-1633392000-1633564799@globalbiodefense.com
SUMMARY:The FDA's Emergency Use Authorization: Lessons Learned from the Past to Guide the Future: A Workshop
DESCRIPTION:The National Academies’ will host a workshop to examine the U.S. Food and Drug Administration’s historic and recent use of the Emergency Use Authorizations (EUAs) for diagnostics\, therapeutics\, and vaccines. \nThe event will provide an overview of the current regulatory framework for EUAs and discuss whether any possible revisions would help to ensure that EUAs are based upon the best and most reliable scientific evidence or enhance public confidence and trust in the EUA process and products. \nThe workshop will also examine EUAs and similar mechanisms used by other entities within the global health regulatory system\, lessons that U.S. and global regulatory and public health partners can learn from one another\, and ways to enhance international cooperation between the FDA and its global partners. \nHighlighted sessions include: \n\nAn Overview of Emergency Use Authorizations and Similar Authorities\nUse of the Emergency Use Authorization During the COVID-19 Pandemic\nCommunication and Transparency for Emergency Use Authorizations Used During the COVID-19 Pandemic\nAn Evaluation of the Process for Authorizing Emergency Use Authorizations and Transitioning to Full Approval\nInternational Cooperation\nHow Should the Emergency Use Authorization Authority be Used for Future Pandemics?\nThe Path Forward: Equities and Enhanced Preparation for the Future\n\nA brief proceedings of the workshop will be published. Please visit NASEM’s FDA’s Emergency Use Authorization: Lessons Learned from the Past to Guide the Future: A Workshop website for more information. \n  \n 
URL:https://globalbiodefense.com/event/the-fdas-emergency-use-authorization-lessons-learned-from-the-past-to-guide-the-future-a-workshop/
CATEGORIES:Conference
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211005T120000
DTEND;TZID=America/New_York:20211005T133000
DTSTAMP:20210925T154350Z
CREATED:20210925T154304Z
LAST-MODIFIED:20210925T154350Z
UID:49825-1633435200-1633440600@globalbiodefense.com
SUMMARY:Complications of COVID-19
DESCRIPTION:Dr. Colleen Kraft\, ASM President Elect\, leads an in-depth discussion on how vaccination and therapeutics have been used to address the long-term complications of COVID-19. \nThis free event is brought to you by the 2021 ASM Clinical Virology Symposium (CVS)\, one of a 4-part CVS Online: SARS-CoV-2 Webinar Series featuring leading experts in the field discussing the most pressing topics around COVID-19. \nABOUT THE SPEAKER \nColleen Kraft\, M.D.\, M.Sc.\, completed residency in Internal Medicine and fellowship in Infectious Diseases in the Department of Medicine\, Emory University\, as well as a Masters in Clinical Research. She pursued post-graduate training in an ACGME-accredited Medical Microbiology fellowship. She ia a Medical Director of the Microbiology section for Emory Medical Laboratories at Emory Healthcare\, as well as program director of the Medical Microbiology fellowship. She is an Associate Professor in the Department of Pathology and Laboratory Medicine and the Division of Infectious Diseases and serves as the associate chief medical officer of Emory University hospital. She rounds on the inpatient infectious diseases consult service so to link clinical microbiology to the bedside. Her research interests are in next-generation sequencing\, microbiome therapeutics\, and healthcare innovation factors. She is very passionate about mentorship of trainees and training the next generation. She believes that creativity and innovation in federal policy can bring about lasting positive change in science. \nThis virtual event is open to ASM members and non-members. Registration opens Tuesday\, Sept. 28\, 2021.
URL:https://globalbiodefense.com/event/complications-of-covid-19/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211005T120000
DTEND;TZID=America/New_York:20211005T153000
DTSTAMP:20210924T193824Z
CREATED:20210924T193720Z
LAST-MODIFIED:20210924T193824Z
UID:49771-1633435200-1633447800@globalbiodefense.com
SUMMARY:Improving Diversity of the Genomics Workforce: A Workshop
DESCRIPTION:The Roundtable on Genomics and Precision Health will host a virtual public workshop that will examine the current state of diversity (e.g.\, racial\, ethnic) of the genetics and genomics workforce\, structural issues that have contributed to diversity challenges\, and potential steps forward. Workshop discussions may address topics such as the impact of racism on the culture of the fields of genetics and genomics; how the genetics/genomics workforce is or is not uniquely affected by structural racism; and the relationship between the lack of diversity in the workforce and patient access to genetic services. \nPanelists will be asked to discuss structural challenges impeding workforce diversity in clinical genetics/genomics\, current efforts to improve workforce diversity in the field\, how those efforts might improve access for patients from underrepresented groups\, and opportunities for professional societies and associations to better support the training and integration of providers from diverse backgrounds. A proceedings in brief of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines. \nBACKGROUND \nThe sequencing of the human genome is rapidly opening new doors to research and progress in biology\, medicine\, and health care. At the same time\, these developments have produced a diversity of new issues to be addressed. The National Academies of Sciences\, Engineering\, and Medicine has convened a Roundtable on Genomics and Precision Health (previously the Roundtable on Translating Genomic-Based Research for Health) that brings together leaders from academia\, industry\, government\, foundations and associations\, and representatives of patient and consumer interests who have a mutual concern and interest in addressing the issues surrounding the translation of genome- based research for use in maintaining and improving health. The mission of the Roundtable is to advance the field of genomics and improve the translation of research findings to health care\, education\, and policy. \nThe Roundtable will discuss the translation process\, identify challenges at various points in the process\, and discuss approaches to address those challenges. The field of genomics and its translation involves many disciplines\, and takes place within different economic\, social\, and cultural contexts\, necessitating a need for increased communication and understanding across these fields. As a convening mechanism for interested parties from diverse perspectives to meet and discuss complex issues of mutual concern in a neutral setting\, the Roundtable: fosters dialogue across sectors and institutions; illuminates issues\, but does not necessarily resolve them; and fosters collaboration among stakeholders. To achieve its objectives\, the Roundtable conducts structured discussions\, workshops\, and symposia. Workshop summaries will be published and collaborative efforts among members are encouraged (e.g.\, journal articles). \nSpecific issues and agenda topics are determined by the Roundtable membership\, and span a broad range of issues relevant to the translation process. Issues may include the integration and coordination of genomic information into health care and public health including encompassing standards for genetic screening and testing\, improving information technology for use in clinical decision making\, ensuring access while protecting privacy\, and using genomic information to reduce health disparities. The patient and family perspective on the use of genomic information for translation includes social and behavioral issues for target populations. There are\nevolving requirements for the health professional community\, and the need to be able to understand and responsibly apply genomics to medicine and public health. \nOf increasing importance is the need to identify the economic implications of using genome-based research for health. Such issues include incentives\, cost-effectiveness\, and sustainability. \nIssues related to the developing science base are also important in the translation process. Such issues could include studies of gene-environment interactions\, as well as the implications of genomics for complex disorders such as addiction\, mental illness\, and chronic diseases. \nLinks to Additional Resources \n\nBonham & Green\, 2021. The genomics workforce must become more diverse: a strategic imperative. The American Journal of Human Genetics 108(1): 3-7.\nChannaoui et al. 2020. Summary report of the 2019 Diversity and Inclusion Task Force of the National Society of Genetic Counselors. Journal of Genetic Counseling 29(2):192-201.\nMann\, S. 2020. Creation of the Minority Genetic Professionals Network to increase diversity in the genetics work force.\nRotenstein et al. 2021. Addressing workforce diversity – A quality-improvement framework. The New England Journal of Medicine. 384: 1083-1086.\nASHG 2021 Meeting- Session on workforce diversity in genomics: Equity and the meaning of inclusion.
URL:https://globalbiodefense.com/event/improving-diversity-of-the-genomics-workforce-a-workshop/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211005T140000
DTEND;TZID=America/New_York:20211006T170000
DTSTAMP:20210923T214504Z
CREATED:20210923T214504Z
LAST-MODIFIED:20210923T214504Z
UID:49734-1633442400-1633539600@globalbiodefense.com
SUMMARY:From Molecular Insights to Patient Stratification
DESCRIPTION:On October 5-6\, 2021\, the Forum on Neuroscience and Nervous System Disorders will host a virtual public workshop that brings together experts and key stakeholders from academia\, industry\, government\, philanthropic foundations\, and disease-focused non-profit organizations to discuss new genetic and neuroscience technologies and explore how these discoveries can be used to elucidate disease mechanisms and to advance the development of biomarkers and targeted therapies for patients with neurological and psychiatric disorders. \nInvited presentations and discussions will be designed to: \n\nExplore the critical need for ancestral diversity and inclusion of individuals with severe or less common disorders—in genetics and the biological specimens needed to follow up on genetics—to advance both scientific analyses and global health equity/precision medicine.\nExamine the use of genetics and other technologies to facilitate identification of genetic variation\, understand the effects of both common and rare variants on disease relevant function\, and gain insights into disease mechanisms and molecular pathways in order to identify biomarkers that enable patient stratification to advance therapeutic development.\nHighlight lessons learned from recent advances in disorders associated with rare\, penetrant genetic variants\, and explore how resulting lessons can be applied to more common neuropsychiatric disorders.\nExplore challenges and promising approaches to nominating and validating stratification\, disease progression\, and treatment biomarkers.\nExplore challenges of designing innovative clinical trials that are based on deep mechanistic understanding of diseases and coupled with target engagement strategies in patients.\nDiscuss a conceptual structure and opportunities to enable advanced technologies and computational approaches to be used more broadly\, effectively\, and rationally for new disorders\, including considering data sharing and stakeholder engagement.\n\nWorkshop Background \nSignificant progress has been seen recently in developing therapies for rare monogenetic disorders such as spinal muscular atrophy and Dravet syndrome. In this domain there is strong collaboration and interest across the R&D landscape\, from academia to biopharma and venture capital. Significant progress has also been seen in fields such as cardiovascular medicine and cancer in improving patient stratification and developing targeted drugs based on genetic findings. In contrast\, progress continues to lag for neuropsychiatric disorders where critical challenges include insufficient mechanistic insights and a lack of biomarkers that can be used to stratify patients within broad symptom-based diagnostic categories. In addition\, minority populations have been largely excluded or underrepresented in genetic studies and clinical trials\, which has been an obstacle in development of appropriate treatments for diverse populations. \nIn the past several years\, there have been important advances in genetic and neuroscience technologies and approaches that have great potential for improving mechanistic understanding of neuropsychiatric diseases and support the development of biomarkers. These include mechanistic and translational studies in patient-derived cells and tissues (iPS derived neurons\, glia\, organoids); high throughput means to analyze combinations of genetic variants; and other tools and computational approaches\, including those developed as part of the BRAIN Initiative. Alongside these technical advances\, it will be critical to increase the ancestral diversity in emerging precision medicine for neuropsychiatric disorders. The time is ripe to explore how these technologies and approaches can be used in the development of biomarkers for patient stratification\, with the ultimate goal of advancing translational efforts and clinical development for rare and common brain disorders.
URL:https://globalbiodefense.com/event/from-molecular-insights-to-patient-stratification/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/09/4863f9d63397e0dfe8c5dcf992536c49.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211006T140000
DTEND;TZID=America/New_York:20211006T153000
DTSTAMP:20210924T031819Z
CREATED:20210924T031819Z
LAST-MODIFIED:20210924T031819Z
UID:49760-1633528800-1633534200@globalbiodefense.com
SUMMARY:Incorporating Lessons Learned During COVID-19 into Future Planning for Emergencies and Disasters
DESCRIPTION:The COVID-19 pandemic has created unprecedented challenges for disaster planners and responders\, bringing to light both shortfalls and opportunities. The rapid pace of operations and ongoing evolution of the public health emergency have prompted modifications to plans and procedures in emergency response; however\, many of the leaders within local and state agencies involved in these activities have not yet had an opportunity to reflect on lessons learned or to incorporate them into emergency plans and mitigation strategies. \nThe observed impacts of the pandemic itself\, as well as other disasters that have intersected with it\, have also shined a light on the deep inequities that contribute to and reproduce unjust outcomes among marginalized communities. \nHow do use what we’ve learned since the appearance of the novel coronavirus to create more equitable and just systems that support the whole community? What steps can we take to better equip disaster preparedness systems to respond to this ongoing threat and future emergencies? This webinar will bring together perspectives from emergency management\, public administration\, public health\, and disaster science to discuss lessons learned from the COVID-19 pandemic and how those lessons can inform future planning for emergencies and disasters. \nModerator: \nNnenia Campbell\, Research Associate\, Natural Hazards Center \nPanelists: \n\nJeffrey Schlegelmilch\, Director\, National Center for Disaster Preparedness\nCurtis Brown\, State Coordinator\, Virginia Department of Emergency Management\nDonell Harvin\, Senior Homeland Security Researcher\, Defense and Political Science\, RAND Corporation\nLeila Darwish\, Independent Community Organizer and Bioremediation Educator\n\nPlease visit NASEM’s Incorporating Lessons Learned During COVID-19 into Future Planning for Emergencies and Disasters meeting page for more information. \n 
URL:https://globalbiodefense.com/event/incorporating-lessons-learned-during-covid-19-into-future-planning-for-emergencies-and-disasters/
CATEGORIES:Conference
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211006T150000
DTEND;TZID=America/New_York:20211006T170000
DTSTAMP:20210924T211020Z
CREATED:20210924T211020Z
LAST-MODIFIED:20210924T211020Z
UID:49774-1633532400-1633539600@globalbiodefense.com
SUMMARY:Respiratory Protection for the Public and Workers without Respiratory Protection Programs at their Workplaces
DESCRIPTION:This is the eighth virtual meeting of a consensus study focused on respiratory protection for the public and workers without respiratory protection programs. During the public portion of this meeting\, the committee will explore current processes and systems for evaluating infectious agents transmissible by inhalation routes and determining the need for public use of respiratory protective devices. \nThe discussion will be led by: \n\nJONATHAN SAMET\, Committee Chair Dean and Professor\, Colorado School of Public Health\nCAPT LISA DELANEY\, Associate Director\, Emergency Preparedness and Response Program\, National Institute for Occupational Safety and Health\nMICHAEL BELL\, Deputy Director\, Division of Healthcare Quality Promotion\, Centers for Disease Control and Prevention\n\nLearn more at NASEM’s Respiratory Protection for the Public and Workers without Respiratory Protection Programs at their Workplaces meeting page. \n 
URL:https://globalbiodefense.com/event/respiratory-protection-for-the-public-and-workers-without-respiratory-protection-programs-at-their-workplaces/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211007T094500
DTEND;TZID=America/New_York:20211007T140000
DTSTAMP:20210925T035750Z
CREATED:20210925T035750Z
LAST-MODIFIED:20210925T035750Z
UID:49811-1633599900-1633615200@globalbiodefense.com
SUMMARY:COVID-19 Vaccines: A Global Experts' Summit
DESCRIPTION:Hear from researchers and public health experts on present and future scenarios as they explore the changing landscape of the virus\, including the Delta variant’s impact on children\, and the latest in vaccine availability\, hesitancy and boosters. \nThis is the last in a series of three virtual events\, hosted by Florida International University in partnership with Baylor College of Medicine\, focusing on the most prevailing issues around COVID-19 and the challenges to preserve global health. \nPlease visit the COVID-19 Vaccines: A Global Experts’ Summit website for more information.
URL:https://globalbiodefense.com/event/covid-19-vaccines-a-global-experts-summit/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20211007T183000
DTEND;TZID=Europe/London:20211007T193000
DTSTAMP:20210925T034618Z
CREATED:20210925T034618Z
LAST-MODIFIED:20210925T034618Z
UID:49808-1633631400-1633635000@globalbiodefense.com
SUMMARY:Poxvirus Research After Smallpox Eradication: New Findings With An Old Vaccine
DESCRIPTION:In 1980 smallpox was declared eradicated after a global vaccination campaign. Today\, only two labs in the world retain variola virus\, the cause of smallpox\, one in the USA and one in Russia – and the World Health Assembly has recommended these virus stocks be destroyed when essential research with variola virus is complete. \nProfessor Geoffrey L. Smith FRS\, winner of the 2020 Leeuwenhoek Medal\, will describe how smallpox was eradicated and what happened afterwards. Despite eradication\, research with vaccinia virus\, the smallpox vaccine\, has endured. This research has provided new ways to make vaccines\, and revealed how our cells respond to virus infection and how the virus escapes these defenses. \nAttending this event\nThis lecture was originally scheduled for March 2020 and has now been rescheduled to take place online. \nLearn more about the Poxvirus Research After Smallpox Eradication: New Findings With An Old Vaccine lecture at The Royal Society website. Register for this event on Eventbrite.
URL:https://globalbiodefense.com/event/poxvirus-research-after-smallpox-eradication-new-findings-with-an-old-vaccine/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211013T173000
DTEND;TZID=America/New_York:20211013T183000
DTSTAMP:20210930T222721Z
CREATED:20210930T215922Z
LAST-MODIFIED:20210930T222721Z
UID:49957-1634146200-1634149800@globalbiodefense.com
SUMMARY:The Future of Global Health Security
DESCRIPTION:Join faculty members from the Schar School’s Biodefense master’s program in a discussion on the future of global health security considering lessons learned from the COVID-19 pandemic. \nPolicy Exchange: The Future of Global Health Security will take place Wednesday\, October 13\, 2021 at 5:30 p.m. ET in a virtual format. This event highlights faculty from GMU Schar School’s Master’s in Biodefense program\, but all prospective students are invited to attend. \nThe COVID-19 pandemic revealed unexpected weaknesses in our preparedness for pandemic threats\, and it continues to pose serious challenges around the world. How are health authorities in the United States and around the world trying to reduce these vulnerabilities so we are better equipped for the next pandemic? \nABOUT THE PANEL \nAdjunct Professor Ashley Grant\, a lead biotechnologist at the MITRE Corporation\, previously served as the senior biological scientist at the Government Accountability Office where she led government-wide technical performance audits focused on biosafety and biosecurity issues. She was an American Association for the Advancement of Science (AAAS) Science and Technology Fellow in the Chemical and Biological Defense Program Office in the Department of Defense and worked at the National Academies of Science on the Committee on International Security and Arms Control. \nAdjunct Professor Andrew Kilianski is the chief intelligence officer for the Department of Defense’s Joint Program Executive Office for Chemical\, Biological\, Radiological and Nuclear Defense (JPEO-CBRND). His work focuses on combating weapons of mass destruction and infectious diseases\, counterintelligence threats to the DoD’s Chemical and Biological Defense Program\, and emerging threat characterization and assessment. Previously\, he served as the CBRN Defense Team Lead at the Defense Intelligence Agency – National Center for Medical Intelligence where he led a team of analysts covering worldwide WMD and medical science and technology developments. \nTerm Assistant Professor Saskia Popescu recently created and disseminated a gap analysis for a six-hospital system to establish vulnerabilities for high-consequence diseases\, helping to guide the creation of a high-consequence disease initiative to enhance readiness at the health care level. This work aided in rapid and coordinated responses to COVID-19. Popescu is certified in infection prevention (CIC)\, hospital preparedness through FEMA’s NIMS\, and pandemic preparedness from the DHS Center for Domestic Preparedness. She currently serves as a member of the Federation of American Scientists (FAS) Coronavirus Taskforce and is a member of the Committee on Data Needs to Monitor Evolution of SARS-CoV-2 within the Health and Medicine Division of the National Academies of Sciences\, Engineering\, and Medicine (NASEM). \nPlease visit the Schar School’s Policy Exchange: The Future of Global Health Security page for more information.
URL:https://globalbiodefense.com/event/gmu-biodefense-future-of-global-health-security-2/
CATEGORIES:Conference,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/09/gmu-biodefense-future-global-health-security-event-banner-lg.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211014
DTEND;VALUE=DATE:20211016
DTSTAMP:20211004T005916Z
CREATED:20211004T005916Z
LAST-MODIFIED:20211004T005916Z
UID:50034-1634169600-1634342399@globalbiodefense.com
SUMMARY:VRBPAC Meeting on Janssen and Moderna COVID-19 Vaccine Boosters
DESCRIPTION:On Oct. 14 and 15\, the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet to discuss the use of booster doses of the Moderna COVID-19 Vaccine and the Janssen COVID-19 Vaccine. Both vaccines are currently authorized for emergency use to prevent COVID-19 in individuals 18 years of age and older. The committee will also hear presentations and discuss the available data on the use of a booster of a different vaccine than the one used for the primary series of an authorized or approved COVID-19 vaccine (heterologous or “mix and match” booster). \nOn Oct. 14\, the committee will discuss an amendment to the emergency use authorization of the Moderna COVID-19 Vaccine for the administration of a booster dose\, in individuals 18 years of age and older. \nOn Oct. 15\, the VRBPAC will discuss amending the emergency use authorization of Johnson and Johnson’s Janssen COVID-19 Vaccine for the administration of a booster dose\, in individuals 18 years of age and older. \nAdditionally\, on Oct. 15\, the committee will hear a presentation from the National Institute of Health’s National Institute of Allergy and Infectious Diseases on the heterologous use of booster doses following the primary series of the three currently authorized or approved COVID-19 vaccines. \nDuring the meeting\, the committee will hear presentations from the companies on the data for their respective vaccines. The FDA will also present its own analyses of each of the manufacturers’ data. There will be an open public hearing each day during which the public will be given an opportunity to provide comments. \nThe FDA intends to make background materials for both VRBPAC meetings available to the public\, including the meeting agendas and committee rosters\, no later than two business days before each meeting. \nThe FDA intends to livestream the VRBPAC meetings on the agency’s YouTube page.
URL:https://globalbiodefense.com/event/vrbpac-meeting-on-janssen-and-moderna-covid-19-vaccine-boosters/
CATEGORIES:Government Hosted,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/10/fda-vrbpac-mix-match-booster-shots-janssen-moderna-boosters-covid-19.jpg
LOCATION:https://www.youtube.com/watch?v=BhlshZ7Lkr0
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211014T110000
DTEND;TZID=America/New_York:20211014T120000
DTSTAMP:20210924T211921Z
CREATED:20210924T211756Z
LAST-MODIFIED:20210924T211921Z
UID:49776-1634209200-1634212800@globalbiodefense.com
SUMMARY:Protecting Health Care in Zones of Conflict: A Webinar
DESCRIPTION:Panelists Leonard Rubenstein (author of the recently released Perilous Medicine: The Struggle to Protect Health Care from the Violence of War) and Joanne Liu will discuss attacks on health workers\, patients\, and hospitals in conflict settings around the world\, along with urgent actions that need to be taken to help ensure safe access to and delivery of health care. The discussion will be moderated by Robert Lawrence. \nSpeakers: \nJoanne Liu\, Professor at the School of Population and Global Health\, McGill University and former International President\, Me´decins Sans Frontie`res \nDr. Joanne Liu has served as International President of Médecins Sans Frontières (MSF) from 2013 to 2019. At the helm of MSF\, she has been a leading voice on medical humanitarian crises\, namely in the Ebola outbreak of West Africa and attacks on hospitals and forced displacement crises\, and has engaged with world leaders at the highest levels. Dr. Liu’s role builds on a career of field work with MSF\, including over 20 medical-humanitarian field assignments. Dr. Liu trained at McGill University School of Medicine in Montreal. She holds a Fellowship in Pediatric Emergency Medicine from New York University School of Medicine and an International Master’s in Health Leadership\, also from McGill University. Dr. Liu’s operational work has ranged from introducing comprehensive care for survivors of sexual violence\, to developing a telemedicine platform for connecting doctors in rural areas with specialists worldwide. Dr. Liu remains a practicing doctor\, both in the field with MSF and also through hospital shifts in her home town of Montreal. She is currently a Professor at the School of Population and Global Health at McGill University with a focus on pandemic preparedness and response and health emergencies. \nLeonard Rubenstein\, Professor of the Practice\, Johns Hopkins Bloomberg School of Public Health \nProf. Leonard Rubenstein is Professor of the Practice at the Johns Hopkins Bloomberg School of Public Health\, and Director of the Program in Human Rights\, Health and Conflict. He is also a core faculty member the Berman\nInstitute of Bioethics and the Center for Humanitarian Health at Johns Hopkins University. Prior to coming to Johns Hopkins in 2009\, he was a Jennings Randolph Senior Fellow at the United States Institute of Peace\, and\nbefore that Executive Director and then President of Physicians for Human Rights. He has a J.D. from Harvard Law School and LL.M. from Georgetown Law School. He is a member of the Council on Foreign Relations. He is the recipient of numerous awards\, including the Congressional Minority Caucuses’ Healthcare Hero Award and the Sidel-Levy Award for Peace of the American Public Health Association. He has appeared before Congress\, the World Health Assembly and the UN Security Council. \nRobert Lawrence (Moderator)\, Center for a Livable Future Professor Emeritus\, John Hopkins Bloomberg School of Public Health and member of the National Academy of Medicine \nRobert Lawrence is the Center for a Livable Future Professor Emeritus and Professor Emeritus of Environmental Health and Engineering at the Johns Hopkins Bloomberg School of Public Health and Professor Emeritus of\nMedicine at the Johns Hopkins School of Medicine. Dr. Lawrence graduated from Harvard Medical School\, trained in Internal Medicine at the Massachusetts General Hospital in Boston\, and served for three years as an Epidemic Intelligence Service Officer\, Centers for Disease Control and Prevention. At the University of North Carolina and as director of the Division of Primary Care at Harvard Medical School and chief of Medicine at the Cambridge Hospital\, he helped develop community health service and training programs. \nDr. Lawrence chaired the first U.S. Preventive Services Task Force from 1984-89 and served on the successor Task Force from 1990-96. From 1991 to 1995\, he served as Director of Health Sciences at the Rockefeller Foundation. He served as associate dean for professional education and programs at JHBSPH from 1995-2006\, established the Center for a Livable Future in 1996\, and served as its director until 2015. As a founding member of Physicians for Human Rights and former member of the Board of Directors\, Dr. Lawrence has participated in human rights investigations on behalf of PHR or other human rights groups to Chile\, Czechoslovakia\, Egypt\, El Salvador\, Guatemala\, the Philippines\, South Africa\, and Kosovo. He is a member of the National Academy of Medicine of the National Academy of Sciences \nPlease visit NASEM’s Protecting Health Care in Zones of Conflict: A Webinar project page for more information. Register on Eventbrite here.
URL:https://globalbiodefense.com/event/protecting-health-care-in-zones-of-conflict-a-webinar/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211019T120000
DTEND;TZID=America/New_York:20211019T133000
DTSTAMP:20210925T154740Z
CREATED:20210925T154620Z
LAST-MODIFIED:20210925T154740Z
UID:49829-1634644800-1634650200@globalbiodefense.com
SUMMARY:Opportunities & Challenges for Next Generation Sequencing of SARS-CoV-2
DESCRIPTION:Dr. Natalie Prystajecky explores how the various public health applications of sequencing has played a crucial role in outbreak response\, surveillance\, emerging variant detection\, and more during the COVID-19 pandemic. \nThis free event is brought to you by the 2021 ASM Clinical Virology Symposium (CVS)\, one of a 4-part CVS Online: SARS-CoV-2 Webinar Series featuring leading experts in the field discussing the most pressing topics around COVID-19. \nABOUT THE SPEAKER \nNatalie Prystajecky\, Ph.D.\nBCCDC Public Health Laboratory \nNatalie Prystajecky\, Ph.D. is a microbiologist at the British Columbia CDC Public Health Laboratory (BCCDC PHL)\, where she oversees the Environmental Microbiology and the Molecular and Microbial Genomics laboratories. She is also Clinical Associate Professor in Pathology and Laboratory Medicine at the University of British Columbia. \nIn her clinical roles and research endeavours\, she uses emerging technologies\, such as genomics\, to improve routine surveillance and outbreak investigations. During the COVID-19 pandemic\, she has provided leadership at the BCCDC PHL to implement genomics and explore opportunities and challenges for next generation sequencing of SARS-CoV-2. \nThis virtual event is open to ASM members and non-members. Registration opens Tuesday\, Sept. 28\, 2021.
URL:https://globalbiodefense.com/event/opportunities-challenges-for-next-generation-sequencing-of-sars-cov-2/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211020T100000
DTEND;TZID=America/New_York:20211021T170000
DTSTAMP:20210925T181613Z
CREATED:20210925T181613Z
LAST-MODIFIED:20210925T181613Z
UID:49859-1634724000-1634835600@globalbiodefense.com
SUMMARY:Advisory Committee on Immunization Practices (ACIP) Meeting
DESCRIPTION:The CDC Advisory Committee on Immunization Practices will convene 20-21 October 2021. ACIP typically holds three meetings each year at CDC in Atlanta\, Georgia to make vaccine recommendations. Due to the coronavirus disease 2019 (COVID-19) pandemic\, ACIP meetings have been held more frequently and have been virtual only (no in-person attendance). \nThe agenda will include discussions on adult immunization schedule\, child/adolescent immunization schedule\, Ebola vaccine\, hepatitis vaccines\, herpes zoster vaccines\, Orthopoxviruses vaccine\, influenza vaccines\, pneumococcal vaccine\, cholera vaccine and tickborne encephalitis vaccine. Recommendation votes on adult immunization schedule\, child/adolescent immunization schedule\, hepatitis vaccine\, herpes zoster vaccine\, Orthopoxviruses vaccine\, pneumococcal vaccine and Ebola vaccine are scheduled. No Vaccines for Children votes are scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit https://www.cdc.gov/​vaccines/​acip/​meetings/​meetings-info.html. \nPublic Participation\nInterested persons or organizations are invited to participate by submitting written views\, recommendations\, and data. Please note that comments received\, including attachments and other supporting materials\, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore\, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name\, contact information\, or other information that identifies you in the body of your comments\, that information will be on public display. CDC will review all submissions and may choose to redact\, or withhold\, submissions containing private or proprietary information such as Social Security numbers\, medical information\, inappropriate language\, or duplicate/near duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. \nWritten Public Comment: The docket will be opened to receive written comments on October 1\, 2021. Written comments must be received on or before October 21\, 2021. \nOral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes including all votes relevant to the ACIP’s Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below. \nProcedure for Oral Public Comment: All persons interested in making an oral public comment at the October 20-21\, 2021 ACIP meeting must submit a request at http://www.cdc.gov/​vaccines/​acip/​meetings/​no later than 11:59 p.m.\, EDT\, October 18\, 2021\, according to the instructions provided. \nIf the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time\, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by October 19\, 2021. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings\, each speaker will be limited to 3 minutes\, and each speaker may only speak once per meeting. \nThe Director\, Strategic Business Initiatives Unit\, Office of the Chief Operating Officer\, Centers for Disease Control and Prevention\, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities\, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. \nACIP consists of 15 experts who are voting members and are responsible for making vaccine recommendations. The Secretary of the U.S. Department of Health and Human Services (DHHS) selects these members after an application and nomination process. Fourteen of these members have expertise in vaccinology\, immunology\, pediatrics\, internal medicine\, nursing\, family medicine\, virology\, public health\, infectious diseases\, or preventive medicine. One member is a consumer representative who provides perspectives on the social and community aspects of vaccination. \nAll of ACIP’s recommendations are posted online. Once they are reviewed and approved by the CDC Director and Department of Health and Human Services\, recommendations are published in the CDC’s MMWR. \nThe MMWR publication represents the official CDC recommendations for immunizations of the U.S. population.
URL:https://globalbiodefense.com/event/advisory-committee-on-immunization-practices-acip-meeting/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211020T190000
DTEND;TZID=America/New_York:20211020T200000
DTSTAMP:20210924T220035Z
CREATED:20210924T214331Z
LAST-MODIFIED:20210924T220035Z
UID:49780-1634756400-1634760000@globalbiodefense.com
SUMMARY:Roundtable on Genomics and Precision Health - Community Open House
DESCRIPTION:The National Academies’ Roundtable on Genomics and Precision Health will host a community open house as an ancillary event to the American Society of Human Genetics 2021 Annual Meeting. Speakers will provide remarks on the Roundtable’s vision of realizing the full potential of health for all through genomics and explore how equity can enable adoption and innovation. Following speaker presentations\, the group will host an open dialogue with the genomics and precision health community. \nBackground \nThe Roundtable on Genomics and Precision Health (previously called the Roundtable on Translating Genomic-Based Research for Health) brings together leaders from government\, academia\, industry\, foundations\, associations\, patient communities\, and other stakeholder groups to meet and discuss global issues surrounding the translation of genomics and genetics research findings into medicine\, public health\, education\, and policy. The primary purpose of the Roundtable is to foster dialogue across sectors and among interested parties and institutions\, and to illuminate and scrutinize critical scientific and policy issues where Roundtable engagement and input will help further the field. \nThe Roundtable membership identifies scientific and policy issues where discussion and collaboration will help enable the translation of genomics into health care applications. Specific issues and agenda topics are determined by the Roundtable members\, and span a broad range of issues relevant to the translation process. Current areas of emphasis include the development of targeted therapeutics and diagnostics\, clinical implementation of genomic medicine\, health IT and mhealth\, the use of genomic information for health care decision making\, next generation sequencing\, using genomic information and data science to generate knowledge for clinical practice and research\, and education and ethical\, legal\, and social issues. \nTo achieve its objectives\, the Roundtable conducts structured discussions\, public workshops\, and symposia and enters into information-gathering activities\, develops authored perspectives\, organizes collaboratives\, and publishes workshop summaries. \nPlease visit NASEM’s Roundtable on Genomics and Precision Health – Community Open House page for more information.
URL:https://globalbiodefense.com/event/roundtable-on-genomics-and-precision-health-community-open-house/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
END:VCALENDAR